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Abstract
Background/Aims: Ursodeoxycholic acid (UDCA) de-
creases biliary secretion of cholesterol and is therefore
used for the dissolution of cholesterol gallstones. It
remains unclear whether these changes in biliary choles-
terol excretion are associated with changes in cholester-
ol synthesis and bile acid synthesis. We therefore stud-
ied the activities of rate-limiting enzymes of cholesterol
synthesis and bile acid synthesis, 3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase and cholesterol 7·-hy-
droxylase, respectively, in normal subjects during UDCA
feeding. Methods: UDCA was given to 8 healthy volun-
teers (5 men, 3 women; age 24–44 years) in a single dose
of 10–15 mg/kg body weight for 40 days. Before and dur-
ing (days 3, 5, 10, 20, 30 and 40) UDCA treatment, urinary
excretion of mevalonic acid and serum concentrations
of 7·-hydroxy-4-cholesten-3-one (7·-HCO) were deter-
mined as markers of cholesterol and bile acid synthesis,
respectively. The Wilcoxon signed rank test and Spear-
man’s rank correlation coefficient were used for statisti-
cal analysis. Results: Cholesterol synthesis and serum
lipid concentrations remained unchanged during UDCA
treatment for 40 days. However, synthesis of bile acids
increased during long-term treatment with UDCA as
reflected by an increase in 7·-HCO serum concentrations
from 39.7 B 21.3 ng/ml (median 32.8 ng/ml) before treat-
ment to 64.0 B 30.4 ng/ml (median 77.5 ng/ml) at days
30–40 of UDCA treatment (p ! 0.05). Conclusions: UDCA
treatment does not affect cholesterol synthesis in the liv-
er, but does increase bile acid synthesis after prolonged
treatment. This may represent a compensatory change
following decreased absorption of endogenous bile
acids as observed with UDCA therapy.
Copyright © 2004 S. Karger AG, Basel
Introduction
In patients with cholesterol gallstones, treatment with
ursodeoxycholic acid (UDCA) decreases biliary secretion
of cholesterol and cholesterol saturation of gallbladder
bile [1, 2]. Moreover, impaired intestinal absorption of
cholesterol has been found by some [3–5], but not all
authors [6, 7] during UDCA treatment. It remains un-
clear, however, whether UDCA therapy also affects cho-
lesterol metabolism. Both stimulatory [8] and inhibitory
effects of UDCA on 3-hydroxy-3-methylglutaryl-coen-
zyme A (HMG-CoA) reductase [9, 10], the rate-limiting
enzyme of cholesterol synthesis, have been reported in
patients with gallstones. The enzymatic activity as well as
mRNA levels of cholesterol 7·-hydroxylase, the rate-lim-
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iting enzyme of the catabolic conversion of cholesterol
into bile acids, were found to be unchanged in human liv-
er tissue after short-term treatment with UDCA [11, 12].
However, increased bile acid synthesis rates were ob-
served in one study after ingestion of UDCA for 6 weeks
[1]. Studies in rats have shown that mRNA levels of
HMG-CoA reductase and cholesterol 7·-hydroxylase do
not change significantly during UDCA feeding [13], while
enzymatic activities of HMG-CoA reductase in liver mi-
crosomes may increase [14]. In primary human hepato-
cytes incubated with UDCA, mRNA levels of cholesterol
7·-hydroxylase remained unchanged [15]. Hence, it re-
mains unclear whether UDCA, either directly by its phar-
macological action or secondary to effects on biliary
excretion or intestinal absorption of cholesterol, affects
the hepatic metabolism of cholesterol.
We therefore studied the activities of two key enzymes
of cholesterol and bile acid synthesis during ingestion of
UDCA in normal subjects. Urinary excretion of meva-
lonic acid (MVA), the enzymatic product of HMG-CoA
reductase, has been shown to reliably reflect HMG-CoA
reductase activity in the liver and was used as a semiquan-
titative marker of cholesterol synthesis [16]. The activity
of cholesterol 7·-hydroxylase was assessed by determina-
tion of serum concentrations of 7·-hydroxy-4-cholesten-
3-one (7·-HCO), an intermediate of the major metabolic
pathway of bile acid synthesis [17, 18]. In addition, we
evaluated the effects of UDCA on serum lipid and apoli-
poprotein (Apo) concentrations.
Subjects and Methods
Subjects and Study Protocol
UDCA was given to 8 healthy subjects (5 men, 3 women; age
24–44 years) for 40 days as a single dose of 10–15 mg/kg body weight
in the evening. The body weight of the subjects was between 54 and
95 kg (median 77 kg), with a body mass index between 21.4 and
30.7 kg/m2 (median 23.2 kg/m2). Blood was drawn in the morning
after a fasting period overnight, and urine was collected overnight for
12 h on days 3, 5, 10, 20, 30 and 40 of UDCA treatment. Mean values
from two time points (before treatment, days 3 and 5, days 10 and 20,
days 30 and 40) were used for further calculations. At all of these time
points, 20 ml of serum was preserved for determinations of serum
lipoprotein profiles, Apo B and Apo A1.
Analytical Methods
Urinary MVA was assayed as a marker of whole-body cholesterol
synthesis by combined gas chromatography-mass spectrometry using
the isotope dilution method described by Lindenthal et al. [16] and
Lindenthal and von Bergmann [19]. Briefly, 100 ng of 2H7-MVA
(MSD Isotopes, Montreal, Canada) was added as internal standard to
400 Ìl of urine. After extraction, purification and derivatization with
methyl-tertiary-butyldimethylsilyl-trifluoroacetamide, the concen-
tration of MVA was analyzed by gas chromatography-mass spec-
trometry on a Finnigan 4000 quadrupole mass spectrometer, SIM
mode. The ion m/z 433 (base peak) was scanned in the selected ion
monitoring mode for endogenous MVA and the ion m/z 440 for 2H7-
MVA. Creatinine in urine was measured by a standard laboratory
procedure.
7·-HCO in serum as a marker of bile acid synthesis was analyzed
by high-performance liquid chromatography (HPLC) according to
the method of Axelson et al. [20]. Briefly, 7·-HCO was extracted in
jacketed glass columns connected to a water bath on octadecylsilane-
bonded silica at 64°C. After a wash with water and 65% aqueous
methanol, 7·-HCO was eluted with hexane-chloroform (80:20, vol/
vol). Analysis was performed by HPLC on a column (250 ! 4.5 mm)
of LiChrospher 100 RP-18 (Merck, Darmstadt, Germany) connected
to a UV detector (SPD-10A, Shimadzu, Kyoto, Japan) at a wave-
length of 254 nm. Acetonitrile-water (98:2, vol/vol) was used as the
mobile phase at a flow rate of 1 ml/min. Serum concentrations of
7·-HCO were calculated from known amounts of 7ß-HCO as inter-
nal standard.
Very-low-density lipoproteins (VLDL) were separated by ultra-
centrifugation (45,000 rpm, 20 h, 4°C, Beckman rotor Ti 50, density
1.006 g/ml). High-density lipoprotein (HDL) cholesterol was deter-
mined in the infranatant after heparin-manganese precipitation of
Apo B-containing lipoproteins. Low-density lipoprotein (LDL) cho-
lesterol was calculated by subtracting HDL cholesterol from total
infranatant cholesterol. Triglyceride and cholesterol levels in serum
and lipoprotein fractions were measured enzymatically by an auto-
analyzer (EPOS, Eppendorf, Hamburg, Germany) using reagents
from Boehringer (Mannheim, Germany). Apo B and Apo A1 concen-
trations were determined by nephelometry (Behring, Marburg, Ger-
many) using antibodies against human Apo B and Apo A1 (anti-Apo
B, anti-Apo A1 from rabbit, Dade Behring, Marburg, Germany).
Data are given as mean B SD or median. The Wilcoxon signed
ranks test for paired samples and Spearman’s rank correlation coeffi-
cient were used for statistical analysis. Data analysis was performed
with the SPSS for Windows program 10.0 (SPSS Inc., Chicago, Ill.,
USA). p values of less than 0.05 were considered statistically signifi-
cant.
Results
Concentrations of urinary MVA were not affected by
UDCA treatment (fig. 1). In contrast, serum concentra-
tions of 7·-HCO increased from 39.7 B 21.3 ng/ml (me-
dian 32.8 ng/ml) before treatment to 64.0 B 30.4 ng/ml
(median 77.5 ng/ml) at days 30–40 of UDCA treatment
(p ! 0.05) (fig. 2). Serum lipoprotein concentrations (cho-
lesterol, triglycerides, LDL cholesterol, HDL cholesterol,
VLDL cholesterol) remained unchanged with the excep-
tion of VLDL triglycerides, which transiently decreased
from 85 to 64 mg/dl at days 10–20 of UDCA treatment
(p ! 0.05) (table 1). Before treatment, serum concentra-
tions of VLDL triglycerides were positively correlated
with serum concentrations of MVA (n = 8; r = 0.79, p =
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Fig. 1. Urinary MVA excretion as a marker of whole-body biosyn-
thesis of cholesterol before and during treatment with UDCA (box
and whiskers plots). Cholesterol synthesis remained unchanged dur-
ing UDCA feeding.
Fig. 2. Serum levels of 7·-HCO as a marker of bile acid synthesis
before and during UDCA feeding (box and whiskers plots). Serum
levels of 7·-HCO remained constant within the first 3 weeks of
UDCA treatment but increased at days 30–40.
Table 1. Serum concentrations of
cholesterol, triglycerides, LDL cholesterol,
HDL cholesterol, VLDL cholesterol, VLDL
triglycerides, Apo A1 and Apo B of 8
volunteers who ingested UDCA for 40 days
Before
treatment
Days 3–5 Days 10–20 Days 30–40
Cholesterol, mg/dl 172B31 170B26 173B21 171B22
Triglycerides, mg/dl 92B50 86B33 91B28 98B22
HDL cholesterol, mg/dl 54B13 53B13 58B13 55B11
LDL cholesterol, mg/dl 104B26 101B24 99B21 100B21
VLDL cholesterol, mg/dl 13B5 15B5 15B6 17B5
VLDL triglycerides, mg/dl 85B43 66B34 64B28* 75B19
Apo A1, mg/dl 157B25 155B23 164B32 161B27
Apo B, mg/dl 91B18 85B19 86B19 87B17
Data are given as mean B SD. * p ! 0.05 compared to pretreatment values.
0.021). Correlations between MVA and 7·-HCO in serum
as well as correlations between each of these two parame-
ters and body weight, body mass index and age did not
reach statistical significance.
Discussion
In the present study, bile acid synthesis was found to
increase in normal subjects after ingestion of UDCA for
more than 4 weeks. The activity of HMG-CoA reductase,
the rate-limiting enzyme of cholesterol synthesis, re-
mained unchanged during UDCA treatment.
Our interpretations are based on the finding that treat-
ment with UDCA for more than 4 weeks increased serum
concentrations of 7·-HCO in healthy subjects. Serum
concentrations of 7·-HCO have been shown to correlate
closely with hepatic cholesterol 7·-hydroxylase activity in
human liver [17] as well as with total synthesis of primary
bile acids as measured by the isotope dilution technique
[18]. Hence, the present data provide evidence that
UDCA enhances the conversion of cholesterol into bile
acids after prolonged treatment. Using the synthetic bile
acid analogue 75selenium homocholic acid taurine, Eusuf-
zai et al. [21] found a dose-dependent reduction of intesti-
nal bile acid reabsorption during administration of
UDCA for 3 weeks. Moreover, Stiehl et al. [22] reported
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impaired absorption of endogenous bile acids in patients
with ileostomies who had received a single dose of
UDCA. These findings are in agreement with kinetic
studies, which have shown increased fractional turnover
rates of cholic acid and chenodeoxycholic acid during
UDCA treatment [1, 2, 4, 23, 24]. These kinetic studies
have also shown that pool sizes of endogenous bile acids
decrease with UDCA treatment. However, there are con-
flicting data regarding changes in bile acid synthesis,
which would be expected to increase in order to compen-
sate for the increased loss of bile acids. While bile acid
synthesis was reported to increase by 40–80% during
UDCA treatment for 5–6 weeks in one study [1], un-
changed cholesterol 7·-hydroxylase activity was found
under short-term conditions [8, 12, 17], and even de-
creased synthesis rates have been reported [23]. Hardison
and Grundy [4] used a balance technique in which they
measured both the daily fecal output of bile acids and the
incorporation of injected [14C]cholesterol into bile acids.
They found that mean total bile acid synthesis increased
from 650 to 800 mg/day when UDCA (15 mg/kg day) was
administered for 1 month.
In the present study, bile acid synthesis remained
unchanged within the first weeks of the study, but increased
after more than 4 weeks. This finding supports the hypoth-
esis that the effects of UDCA on cholesterol and bile acid
metabolism may change over time [8]. The lack of short-
term effects indicates that UDCA either has no direct effect
on bile acid synthesis or moderately inhibits bile acid syn-
thesis, thereby neutralizing the stimulatory effect of bile
acid malabsorption in the first weeks of UDCA treatment.
This hypothesis is in agreement with the fact that UDCA
binds only weakly to the farnesoid X receptor, which has
been shown to inhibit cholesterol 7·-hydroxylase gene
expression after binding of endogenous bile acids [25, 26].
Since UDCA treatment results in a continuous loss of
endogenous bile acids, the observed increase in cholesterol
7·-hydroxylase activity is probably due to an increasing
shortage of endogenous bile acids over time.
Whole-body cholesterol synthesis as measured by uri-
nary mevalonate excretion remained unchanged during
the 40-day regimen of UDCA treatment in our study.
This finding is in agreement with data of Angelin et al.
[27], who observed unchanged hepatic HMG-CoA reduc-
tase activity in patients with gallstones after 6 weeks of
treatment with UDCA. However, Maton et al. [9] found
that hepatic HMG-CoA reductase activity was reduced to
35% after 3–5 months of UDCA treatment, and Salen et
al. [10] reported a threefold decrease in 2 patients after 1
year of UDCA treatment. Even though data on changes in
hepatic HMG-CoA reductase activity after longer treat-
ment periods are conflicting, decreased biliary excretion
of cholesterol obviously does not affect cholesterol synthe-
sis under short-term conditions. These findings corre-
spond to recent observations of Hillebrant et al. [28], who
studied the effects of combined treatment with pravastat-
in and UDCA on hepatic cholesterol metabolism. Prava-
statin did not further reduce the cholesterol saturation of
bile in patients with gallstones treated with UDCA,
although hepatic cholesterol synthesis was inhibited. Our
results support the concept that de novo synthesis of cho-
lesterol is not particularly important for biliary cholester-
ol secretion in humans.
The effects of UDCA on serum lipoprotein profiles
have mainly been studied in patients with gallstone dis-
ease. Erlinger et al. [29] treated 197 patients at daily doses
of 2.1–16.2 mg/kg for up to 1 year and observed no signif-
icant influence of UDCA treatment on serum cholesterol
and triglycerides. Fromm et al. [30] found no change in
serum cholesterol and triglyceride in serum in patients
with gallstones who were fed UDCA for 1 year at doses of
400–800 mg/day. In the present study on normal subjects,
we were unable to detect changes in cholesterol and tri-
glyceride in serum, including LDL cholesterol, HDL cho-
lesterol and VLDL cholesterol. However, there was a tran-
sient decrease in VLDL triglycerides at days 10–20. This
finding is in agreement with studies demonstrating an
inhibitory effect of bile acids, including UDCA, on VLDL
lipoprotein secretion in rat hepatocytes in primary culture
[31]. Moreover, serum concentrations of VLDL triglycer-
ides were positively correlated with serum concentrations
of MVA before, but not during UDCA treatment. A simi-
lar correlation between cholesterol synthesis and secretion
of VLDL Apo B was described by Watts et al. [32] in nor-
molipidemic subjects, indicating that in vivo cholesterol
synthesis is a determinant of hepatic secretion of Apo B.
In conclusion, the present study shows that ingestion of
UDCA moderately increases bile acid synthesis after
treatment periods of 4–6 weeks. Moreover, from the tran-
sient decrease in VLDL triglycerides during UDCA feed-
ing, we cannot exclude the possibility that UDCA affects
VLDL secretion.
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